Nanotech bill
This article was originally published in The Gray Sheet
Executive Summary
The Nanotechnology Safety Act of 2010, introduced Jan. 21 by Sens. Mark Pryor, D-Ariz., and Benjamin Cardin, D-Md., would establish a program within FDA "to assess the health and safety implications of nanotechnology in everyday products and develop best practices for companies who employ nanotechnology," according to Pryor. The program would be carried out at FDA's National Center for Toxicology Research in Jefferson, Ariz., and at FDA headquarters in White Oak, Md. Nanotechnology "has hundreds of promising applications," Pryor said. "As these products are developed and used, we must understand any potential risks to human health, safety or the environment.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.